Metastatic Breast Cancer
News
Pembro benefits in mTNBC regardless of chemo type
News
First-in-class ADC has benefit across mTNBC subgroups
For women with pretreated metastatic triple-negative breast cancer, sacituzumab govitecan improved outcomes regardless of target protein...
News
CTCs predict overall survival in metastatic breast cancer
New data seem to support using circulating tumor cells to assess treatment efficacy in practice, but an expert has doubts.
News
Should CTCs guide treatment choice in HR+, HER2– breast cancer?
Survival outcomes were similar whether treatment choice was guided by circulating tumor cell counts or clinical factors.
News
Pembrolizumab approved for triple-negative breast cancer
This is the first breast cancer indication for pembrolizumab.
News
Divergent findings with paclitaxel and nab-paclitaxel in TNBC
Atezolizumab may improve survival when it’s added to nab-paclitaxel but not paclitaxel, studies suggest.
News
First-in-class ADC ups survival in mTNBC
Sacituzumab govitecan prolonged progression-free and overall survival.
News
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
News
Atezolizumab TNBC indication ‘in jeopardy’ because of phase 3 results
Negative results from the IMpassion131 trial may jeopardize the U.S. approval of atezolizumab in breast cancer.
News
First guideline on NGS testing in cancer, from ESMO